{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35950011",
  "DateCompleted": {
    "Year": "2022",
    "Month": "08",
    "Day": "12"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "09",
    "Day": "29"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "07",
        "Day": "30"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "2270965",
      "10.1155/2022/2270965"
    ],
    "Journal": {
      "ISSN": "2054-4200",
      "JournalIssue": {
        "Volume": "2022",
        "PubDate": {
          "Year": "2022"
        }
      },
      "Title": "Global health, epidemiology and genomics",
      "ISOAbbreviation": "Glob Health Epidemiol Genom"
    },
    "ArticleTitle": "Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage.",
    "Pagination": {
      "StartPage": "2270965",
      "MedlinePgn": "2270965"
    },
    "Abstract": {
      "AbstractText": [
        "Rapid identification and tracking of emerging SARS-CoV-2 variants are critical for understanding the transmission dynamics and developing strategies for interrupting the transmission chain. Next-Generation Sequencing (NGS) is an exceptional tool for whole-genome analysis and deciphering new mutations. The technique has been instrumental in identifying the variants of concern (VOC) and tracking this pandemic. However, NGS is complex and expensive for large-scale adoption, and epidemiological monitoring with NGS alone could be unattainable in limited-resource settings. In this study, we explored the application of RT-qPCR-based detection of the variant identified by NGS. We analyzed a total of 78 deidentified samples that screened positive for SARS-CoV-2 from two timeframes, August 2020 and July 2021. All 78 samples were classified into WHO lineages by whole-genome sequencing and then compared with two commercially available RT-qPCR assays for spike protein mutation(s). The data showed good concordance between RT-qPCR and NGS analysis for specific SARS-CoV-2 lineages and characteristic mutations. RT-qPCR assays are quick and cost-effective and thus can be implemented in synergy with NGS for screening NGS-identified mutations of SARS-CoV-2 for clinical and epidemiological interest. Strategic use of NGS and RT-qPCR can offer several COVID-19 epidemiological advantages."
      ],
      "CopyrightInformation": "Copyright \u00a9 2022 Rob E. Carpenter et al."
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-2818-7474"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Advanta Genetics, 10935 CR 159, Tyler, TX 75703, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "University of Texas at Tyler, 3900 University Boulevard, Tyler, TX 75799, USA."
          }
        ],
        "LastName": "Carpenter",
        "ForeName": "Rob E",
        "Initials": "RE"
      },
      {
        "Identifier": [
          "0000-0001-9067-2406"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "ICMR-National Institute of Research in Tribal Health, Jabalpur, MP 482003, India."
          },
          {
            "Identifier": [],
            "Affiliation": "RetroBioTech LLC, Coppell, TX 75019, USA."
          }
        ],
        "LastName": "Tamrakar",
        "ForeName": "Vaibhav",
        "Initials": "V"
      },
      {
        "Identifier": [
          "0000-0002-4297-0297"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "RetroBioTech LLC, Coppell, TX 75019, USA."
          }
        ],
        "LastName": "Chahar",
        "ForeName": "Harendra",
        "Initials": "H"
      },
      {
        "Identifier": [
          "0000-0002-6990-7503"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Advanta Genetics, 10935 CR 159, Tyler, TX 75703, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "University of Miami Miller School of Medicine, 1600 NW 10th Ave, Miami, FL 33136, USA."
          }
        ],
        "LastName": "Vine",
        "ForeName": "Tyler",
        "Initials": "T"
      },
      {
        "Identifier": [
          "0000-0001-8886-1101"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Advanta Genetics, 10935 CR 159, Tyler, TX 75703, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "RetroBioTech LLC, Coppell, TX 75019, USA."
          }
        ],
        "LastName": "Sharma",
        "ForeName": "Rahul",
        "Initials": "R"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Glob Health Epidemiol Genom",
    "NlmUniqueID": "101703450",
    "ISSNLinking": "2054-4200"
  },
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "diagnosis",
        "epidemiology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "High-Throughput Nucleotide Sequencing"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "The authors declare that they have no conflicts of interest."
}